Our first
liver therapeutic development program is for methylmalonic acidemia (MMA), a serious and often life - threatening rare liver disease; it is primarily a pediatric disease with onset in early infancy.
Not exact matches
Co-lead author, Doctor Mohammed Eslam, said this discovery holds great promise for the
development of effective
therapeutic treatments for
liver disease.